IBA selects Dassault Systèmes' 3DEXPERIENCE platform to support development of cancer therapy solutions

Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, announced today that Ion Beam Applications SA (IBA), the leading medical device manufacturer and pioneer in proton beam therapy for cancer treatment, selected the 3DEXPERIENCE platform based on V6 architecture, and its "Licensed to Cure for Medical Device" industry solution experience. With "Licensed to Cure for Medical Device", IBA will support the development processes of its medical accelerator solutions.

The changing medical needs of a growing world population, along with advances in medical research, place extreme challenges on medical device manufacturers to accelerate development of innovative and safe equipment that comply with stringent national and international regulations. IBA wanted to transition from a labor-intensive engineered-to-order approach to a standardized collaborative development approach that results in an extensive series of production-ready machines that fit a variety of complex customers' demands.

Thanks to "Licensed to Cure for Medical Device," IBA's global teams get a centralized access to the most up to date design, regulatory and quality information, ensuring regulatory compliance. Users spend little time looking for product data when they need to respond to a regulatory body's request for information. IBA has full traceability and can tightly secure its corporate intellectual property. This helps maintain its competitive edge against other medical device companies.

"With 'Licensed to Cure for Medical Device' we will have a single unifying development framework in which we can capitalize all our data, processes and methodologies for future reuse, and from there improve the productivity of all downstream processes." said Thomas Canon, PLM Program Manager at IBA.

"Medical device manufacturers have a dual responsibility: to patients for innovative therapeutic solutions, and to regulatory bodies that must ensure that their equipment abides by stringent safety and quality protocols," said Monica Menghini, Executive Vice President, Corporate Strategy, Industry and Marketing, Dassault Systèmes. "The integrated 'Licensed to Cure for Medical Device' industry solution experience gives the Life Science Industry a competitive means to provide a faster reply to operators' needs and, ultimately, faster accessibility to therapies for the patients."